Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study.
OBJECTIVE
To evaluate the efficacy and tolerability of fluticasone propionate (FP) hydrofluoroalkane (HFA) in children age 1 to < 4 years with asthma.


METHODS
Children were assigned (2:1) to receive FP HFA 88 mug (n = 239) or placebo HFA (n = 120) twice daily through a metered-dose inhaler with a valved holding chamber and attached facemask for 12 weeks. The primary efficacy measure was mean percent change from baseline to endpoint in 24-hour daily (composite of daytime and nighttime) asthma symptom scores.


RESULTS
The FP-treated children had significantly greater (P < or = .05) reductions in 24-hour daily asthma symptom scores (-53.9% vs -44.1%) and nighttime symptom scores over the entire treatment period compared with the placebo group. Daytime asthma symptom scores and albuterol use were slightly more decreased with FP than with placebo; however, the differences were not statistically significant. Increases in the percentage of symptom-free days were comparable. The percentage of patients who experienced at least 1 adverse event was similar in the 2 groups. Baseline median urinary cortisol excretion values were comparable between the groups, and there was little change from baseline at endpoint. FP plasma concentrations demonstrated that systemic exposure was low.


CONCLUSIONS
FP HFA 88 mug twice daily was effective and well tolerated in pre-school-age children with asthma.
Qaqundah
Paul Y
PY
Pediatric Medical Care Group, Inc, Huntington Beach, CA, USA. pqaqundah@aol.com
Sugerman
Robert W
RW
Ceruti
Elaina
E
Maspero
Jorge Fernando
JF
Kleha
Joseph F
JF
Scott
Catherine A
CA
Wu
Wei
W
Mehta
Rashmi
R
Crim
Courtney
C
D000280:Administration, Inhalation; D000335:Aerosol Propellants / Q000627:therapeutic use; D000420:Albuterol / Q000627:therapeutic use; D000730:Androstadienes / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002675:Child, Preschool; D002940:Circadian Rhythm / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D000068298:Fluticasone; D006801:Humans; D006845:Hydrocarbons, Fluorinated / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D036501:Metered Dose Inhalers; D016896:Treatment Outcome; D005466:Fluorocarbons
D000335:Aerosol Propellants; D000420:Albuterol; D000730:Androstadienes; D001993:Bronchodilator Agents; D000068298:Fluticasone; D006845:Hydrocarbons, Fluorinated; C094049:apaflurane; D005466:Fluorocarbons